Current stock page

Financial Data

AUPH Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

AUPHAurinia Pharmaceuticals Inc.

Healthcare / Biotechnology

Leader

Sector Leader

BullishEdge 10/10
$15.73−$0.48 (−2.96%)

Latest quote

  • Momentum
    73
  • Value
    84
  • Quality
    77
  • Risk resilience
    68
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$83.7M$83.22M$77.71M$77.11M$73.47M$70.01M$62.47M$59.87M
Gross Profit$75.39M$76.67M$71.2M$68.64M$64.96M$62.89M$53.89M$54.32M
Operating Income$35.36M$46.34M$41.42M$33.24M$29.75M$20.08M$21.85M-$1.67M
Net Income$31.7M$37.41M$34.36M$210.79M$31.55M$21.51M$23.34M$1.43M
EPS$0.24$0.29$0.26$1.58$0.23$0.16$0.16$0.01
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow$46.37M$52.17M$32.56M$44.57M$44.45M$44.24M$1.3M$30.11M
Capital Expenditure-$24K$179-$39K-$69.76K-$65K-$98K-$17K-$56K
Free Cash Flow$46.34M$52.17M$32.52M$44.5M$44.38M$44.14M$1.28M$30.06M
Net Cash Provided By Operating Activities$46.37M$52.17M$32.56M$44.57M$44.45M$44.24M$1.3M$30.11M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$825.7M$792.26M$724M$751.59M$527.53M$502.56M$504.85M$550.65M
Total Debt$58.66M$60.42M$68.64M$74.81M$78.21M$81.83M$77.91M$79.37M
Cash And Cash Equivalents$46.15M$179.83M$41.01M$80.21M$73.19M$53M$66.43M$83.43M
Total Liabilities$168.19M$177.4M$156.37M$170.26M$161.76M$167.26M$154.66M$173.17M
Total Stockholders Equity$657.52M$614.86M$567.63M$581.33M$365.77M$335.3M$350.19M$377.48M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio7.086.866.996.7524.9321.8328.31193.84
P/B ratio3.383.53.673.335.313.953.222.95
P/S ratio6.52———————
Debt To Equity0.090.10.120.130.210.240.220.21
Free Cash Flow Yield7.89%8.06%7.94%6.93%6.18%6.98%5.67%3.96%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio7.086.866.996.7524.9321.8328.31193.84
P/B ratio3.383.53.673.335.313.953.222.95
P/S ratio6.52———————
Return On Equity47.80%51.09%52.54%49.40%21.28%18.08%11.38%1.52%
Debt To Equity0.090.10.120.130.210.240.220.21

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe6.64x
Pb3.19x
Revenue Growth Yoy13.93%
EPS Growth Yoy4.35%
Gross Margin90.73%
Operating Margin48.60%
ROE51.92%
ROIC20.91%
Debt To Equity0.09
FCF Yield8.33%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$15.73
Volume691,300
RSI (14)39.95
MACD-0.11
MACD signal0.01
MACD histogram-0.12
ADX (14)17.25
SMA (50)$16.48
SMA (200)$15.73
ATR (14)$0.52
Historical volatility (annualized)36.69%
Volume (20-day average)903,495

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score68/100
Beta0.64
Annual volatility35.52%
Max Drawdown-21.75%
Sharpe Ratio0.16
VaR (95%, 1-day)-3.39%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

AUPH Financial Data FAQ

What is Aurinia Pharmaceuticals Inc.'s revenue?

Aurinia Pharmaceuticals Inc.'s revenue is one of the core financial data points for AUPH. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Aurinia Pharmaceuticals Inc.'s revenue growing?

Revenue growth shows whether Aurinia Pharmaceuticals Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is AUPH's EPS?

AUPH's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Aurinia Pharmaceuticals Inc.'s net income?

Aurinia Pharmaceuticals Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Aurinia Pharmaceuticals Inc. generate?

Free cash flow shows how much cash Aurinia Pharmaceuticals Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Aurinia Pharmaceuticals Inc. have?

Cash and debt help frame AUPH's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.